ERBB2 and neoplasm: In addition, HER2/neu-expressing EVs stimulate stronger HER2-specific CTL responses, eradicating 90% of HER2-overexpressing 4T1 tumor cells, while HER2-expressing EV-induced CTL responses only eliminate 53% of targets.